2 Stocks Under $20 to Watch
Here are two interesting companies under $20.
avatar
Mike Sakuraba graduated with double major of English and Economics. Part time writer, part time investor, full time dad. Mike loves writing about technology, sports, and investing.
2022-09-17 11:20

More Cheap Stocks For Your Watchlist
Readers seemed to enjoy the article I posted last week about 3 Stocks Under $10 to Watch. I get it, we’re all down bad right now. We want some discounted stocks to add for the next bull run. I have to give the disclaimer again that this is not financial advice, but merely a look at some stocks that I think are lower than the intrinsic value of the company, especially over the next ten to twenty years.
2 Stocks Under to Watch
So while last week we looked at stocks that are about as low as I would look at in Palantir (NYSE:PLTR), SoFi (NASDAQ:SOFI), and StoneCo (NASDAQ:STNE), this week we move a tier higher to the $10-20 price range. This isn’t to say that stock price is the only thing you should look at, but we can project forward-looking price multiples for the future. I won’t go too much into that but here are two stocks that I think can provide some nice returns whenever we turn back bullish.

ClearPoint Neuro (NASDAQ:CLPT)
Here’s an interesting company: ClearPoint Neuro is operated mostly by ex-Phillips employees and executives. Phillips is one of the global leaders in medical technology and this group is clearly applying that experience to ClearPoint’s business. This company is more of a pick and shovel play for the biotech industry, and its focus isn’t necessarily centralized on clinical trials like other firms. As its name suggests, ClearPoint is in the neurological industry and is developing some therapies and technology to deal with issues that revolve around brain health. It recently received FDA Clearance for its Maestro Brain Model, which provides immediate and real-time analysis of brain MRI images. After a stock sale in February to raise capital, the stock has mostly traded within range and has performed a lot better than other biotech stocks in this bear market. ClearPoint projects future sales of $4 billion annually, which is an incredible growth trajectory over the next decade. If you believe in brain health and want a somewhat safer biotech stock, take a look at ClearPoint Neuro.

Coupang (NYSE:CPNG)
I wrote about the Korean eCommerce giant Coupang when it first went public a couple of years ago. It was expensive back then but has since lost about 65% since its IPO. Anyone who follows Asian economies knows that COVID has really ravaged the likes of Japan, China, and Korea. This has nothing to do with eCommerce demand dropping off in a country like Korea that has one of the highest smartphone adoption in the world. Coupang has actually increased its market share in South Korea, even as its stock price has decreased. This is an interesting negative correlation that shows us the stock is likely suffering more from the bear market punishing speculative growth companies. South Korea is one market where Amazon (NASDAQ:AMZN) simply has not entered, so Coupang is still the biggest fish in the water. Coupang is moving in the same direction as companies like Tencent and AliBaba (NYSE:BABA) with food delivery, video streaming, and fintech, as well as expanding to international markets. At just $17 per share, I think this company has a massive runway ahead of it and is worth watching over the next few years as it turns to profitability.


Disclaimer: I have no positions in any of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article. All information should be independently verified and should not be relied upon for purposes of transacting securities or other investments. See terms for more info.

Rate this article

positive
negative
Published On
2022-09-17 11:20

avatar
About the Author
Mike Sakuraba graduated with double major of English and Economics. Part time writer, part time investor, full time dad. Mike loves writing about technology, sports, and investing.

Analyst Ratings
Target Price$ 0
# of Analysts0
Last updated

buy-coffee
You've read 1 article in the last year
..thank you for supporting us and for visiting our site. Unlike many other sites, The Dog of Wall Street is available for everyone to read. Our focus is to provide great content for free. Do you like what we are doing? Buy us a cup coffee. It is the fuel that keeps us going..

3 Final Earnings I'm Watching For the Coming Week
There are still some major companies reporting this week.
By Mike Sakuraba | 4 weeks ago

Don’t Be Caught In The Bed and Beyond Meme Stock Madness!
Meme stock valuation depends on the hype, not the stock's fundamentals.
By Precious Njoku | 1 month ago

Stocks Buffett's Berkshire Hathaway (BRKB) Sold Off This Year
This year, Warren Buffett has sold a considerable number of stocks.
By Precious Njoku | 1 month ago

BBBY Short Squeeze: Have We Learned Our Lesson Yet?
Ryan Cohen Does Not Owe Us Anything.
By Mike Sakuraba | 1 month ago

Why Electric Vehicle Stocks Have an Uphill Climb
Rivian Cancels Pre-Orders, Short Seller Bets Against Tesla.
By Mike Sakuraba | 1 month ago

3 More Earnings to Focus On Next Week
Here are actually a few major companies that will be reporting next week.
By Mike Sakuraba | 1 month ago

Why Softbank's Sale of Alibaba Stock was a Good Move
Softbank Group Corp. (OTCMKTS: SFTBY),a Japanese multinational company, has gained much reputation over the years for investing in startups and making money.
By Precious Njoku | 1 month ago